Back to Stocks

KROS

Keros Therapeutics, Inc.
2 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Keros Therapeutics has successfully transitioned from a broad, cash-intensive biotech into a disciplined, catalyst-driven entity.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the reported cash hoard, Keros faces a precarious financial reality. The perceived stability of the balance sheet is largely a result of a one-time $200 million upfront fee from Takeda, which does not represent recurring revenue.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every KROS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical inflection point, having traded breadth for depth. The successful transition of elritercept to Takeda has provided a temporary financial fortress, but the ultimate value of the company now rests on binary clinical outcomes for rinvatercept. Investors are essentially weighing a lean, de-risked operational model against the inherent volatility of early-stage clinical trials. The core tension for shareholders is whether the current cash position is a genuine bridge to 2028 or a temporary cushion that will be rapidly consumed by upcoming trial costs. While the reduction in operating expenses is a positive signal of management discipline, the lack of recurring revenue makes Keros a high-beta play on its TGF-β platform's ability to deliver disease-modifying results in neuromuscular markets.

Selected Quarter

Core Takeaway

Keros has successfully reduced its burn and offloaded elritercept development to Takeda, shifting its profile from a cash-burning developer to a catalyst-driven royalty play.

Investor Lens

The trade-off is between a disciplined, low-burn cost structure and the binary risk of upcoming Phase 2 clinical readouts.

Watch Next

Initiation of rinvatercept Phase 2 trials in DMD (Q3 2026) and ALS (H2 2026).

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 14

R&D expenses plummeted 67% year-over-year due to strategic pivot and partnership transition.

margin expansion
80%
bearishMay 14

Net loss of $23.7 million for the quarter, though expected for clinical-stage biotech.

earnings miss
40%
neutralMay 14

Workforce reduced by approximately 45% as part of corporate restructuring.

management change
30%
bullishMay 14

R&D expenses plummeted 67% year-over-year due to strategic pivot and partnership transition.

margin expansion
80%
bearishMay 14

Net loss of $23.7 million for the quarter, though expected for clinical-stage biotech.

earnings miss
40%
neutralMay 14

Workforce reduced by approximately 45% as part of corporate restructuring.

management change
30%

Filing History

10-QMay 14, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical inflection point, having traded breadth for depth. The successful transition of elritercept to Takeda has provided a temporary financial fortress, but the ultimate value of the company now rests on binary clinical outcomes for rinvatercept. Investors are essentially weighing a lean, de-risked operational model against the inherent volatility of early-stage clinical trials. The core tension for shareholders is whether the current cash position is a genuine bridge to 2028 or a temporary cushion that will be rapidly consumed by upcoming trial costs. While the reduction in operating expenses is a positive signal of management discipline, the lack of recurring revenue makes Keros a high-beta play on its TGF-β platform's ability to deliver disease-modifying results in neuromuscular markets.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.